Table 1.
5152s baseline | 5152s week 24 | IU on drug | IU not on drug | |
---|---|---|---|---|
N | 82 | 79 | 49 | 47 |
Age, years (mean) | 35.6±8.3 | — | 40.3±8.1 | 37.0±11.5 |
Male sex | 76 (92%) | — | 32 (65%) | 38 (81%) |
Race/ethnicity | ||||
White non-Hispanic | 45 (55%) | — | 28 (57%) | 28 (60%) |
Hispanic | 12 (15%) | — | 4 (8%) | 1 (2%) |
Black | 23 (28%) | — | 17 (35%) | 18 (38%) |
Unknown | 2 (2%) | — | ||
Time on ART | — | 24 weeks | 39.6±29.5 months [46] | — |
BMI, kg/m2 | 25.1 (22.8–27.7) [77] | 26.0 (23.5–28.4) [73] | 25.5 (21.7–28.6) [48] | 25.3 (22.4–28.0) [47] |
HOMA-IR | 1.37 (0.78–2.33) [73] | 1.42 (0.02–2.18) [73] | 2.29 (1.60–2.76) [43] | 2.39 (1.96–3.41) [44] |
Total cholesterol, mg/dl | 144 (128–163) [81] | 180 (159–217) [79] | 182 (164–221) [43] | 155 (136–169) [44] |
Triglycerides | 113 (90–178) [81] | 177 (100–275) [79] | 129 (85–182) [48] | 99 (77–157) [47] |
HDL cholesterol | 31 (26–36) [80] | 41 (34–50) [76] | 47 (35–55) [45] | 38 (28–45) [45] |
LDL cholesterol | 88 (66–102) [78] | 96 (81–118) [68] | 104 (90–132) [45] | 95 (72–110) [44] |
HDL particles, nmol/liter | 22.7 (19.9–26.1) [80] | 29.0 (25.2–33.2) [76] | 25.6 (22.8–28.8) [49] | 23.1 (19.5–26.3) [44] |
Large HDL particles | 3.2 (2.0–4.9) [80] | 4.2 (1.6–7.3) [76] | 4.1 (2.0–7.3) [49] | 3.4 (1.8–4.4) [44] |
LDL particles | 1124 (874–1298) [80] | 1268 (995–1602) [76] | 1103 (881–1317) [49] | 1060 (821–1352) [44] |
CD4+ cells/mm3 | 245 (119–356) [78] | 376 (252–557) [79] | 464 (368–735) [48] | 335 (218–546) [47] |
Log10 HIV RNA copies/ml | 4.93±0.63 [82] | 1.95±0.74 [79] | 2.85±0.72 [46] | 4.22±1.00 [44] |
% HIV RNA <400 copies/ml | 0 [82] | 92 [79] | 85 [46] | 9 [44] |
sCD14 (106 pg/ml) | 2.12 (1.81–2.57) [82] | 2.08 (1.60–2.55) [79] *p=0.4 | 1.67 (1.53–1.97) [49] | 1.68 (1.38–2.03) [42] |
LPS (pg/ml) | 28.8 (16.5–42.0) [82] | 35.1 (17.8–56.6) [79] *p=0.02 | 27.6 (17.4–38.8) [47] | 21.4 (12.9–30.2) [40] |
p-value for the change from baseline to week 24.
Values are mean±SD or median (25–75% percentile). Numbers in brackets represent the number of subjects who had that variable measured.
ART, antiretroviral therapy; sCD14, soluble CD14; LPS, lipopolysaccharide; IU, Indiana University; BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.